478 reports of this reaction
1.5% of all CYCLOBENZAPRINE HYDROCHLORIDE reports
#11 most reported adverse reaction
DYSPNOEA is the #11 most commonly reported adverse reaction for CYCLOBENZAPRINE HYDROCHLORIDE, manufactured by Cephalon, LLC. There are 478 FDA adverse event reports linking CYCLOBENZAPRINE HYDROCHLORIDE to DYSPNOEA. This represents approximately 1.5% of all 32,882 adverse event reports for this drug.
Patients taking CYCLOBENZAPRINE HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for CYCLOBENZAPRINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for CYCLOBENZAPRINE HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 478 FDA reports for CYCLOBENZAPRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.5% of all adverse event reports for CYCLOBENZAPRINE HYDROCHLORIDE, making it a notable side effect.
If you experience dyspnoea while taking CYCLOBENZAPRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.